Stroke. Stroke, not specified as haemorrhage or infarction
Conditions
Interventions
Intervention 1: Intervention: Memantine 20 mg TID plus Atorvastatin 20 mg BID for 5 days then Memantine 10 mg BID and Atorvastatin 40 mg daily for 3 months. Intervention 2: Control: Atorvastatin 20 mg
Treatment - Drugs
Intervention: Memantine 20 mg TID plus Atorvastatin 20 mg BID for 5 days then Memantine 10 mg BID and Atorvastatin 40 mg daily for 3 months.
Control: Atorvastatin 20 mg BID for first 5 days and 40 mg daily for 3 months
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: inclusion criteria: all patients with stroke exclusion criteria: hemorrhagic stroke; sensitivity to Memantine or Statins; acute or chronic renal failure; acute or chronic hepatic disease; acute MI (<48 hours); autoimmune diseases; administration of Statin or Memantine during 6 months before stroke
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Matrix metaloproteinase 2. Timepoint: Day 1, 3, 5. Method of measurement: ELISA kits.;Matrix metaloproteinase 9. Timepoint: Day 1, 3, 5. Method of measurement: ELISA kits. | — |
Secondary
| Measure | Time frame |
|---|---|
| Barthel index. Timepoint: 3 months after ischemic stroke. Method of measurement: Questionnaire.;Motality. Timepoint: 90 days after stroke. Method of measurement: check by phone.;National Institute for Health Stroke Score (NIHSS). Timepoint: Days 1 and 5 after stroke. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Sistanizad
Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences
Outcome results
None listed